RU2007119067A - MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA - Google Patents

MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA Download PDF

Info

Publication number
RU2007119067A
RU2007119067A RU2007119067/15A RU2007119067A RU2007119067A RU 2007119067 A RU2007119067 A RU 2007119067A RU 2007119067/15 A RU2007119067/15 A RU 2007119067/15A RU 2007119067 A RU2007119067 A RU 2007119067A RU 2007119067 A RU2007119067 A RU 2007119067A
Authority
RU
Russia
Prior art keywords
diarrhea
ramosetron
women
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2007119067/15A
Other languages
Russian (ru)
Other versions
RU2351327C2 (en
Inventor
Акито НИСИДА (JP)
Акито НИСИДА
Акира НИВА (JP)
Акира НИВА
Ютака АЦУТА (JP)
Ютака АЦУТА
Original Assignee
Астеллас Фарма Инк. (Jp)
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2004/000896 external-priority patent/WO2004066998A1/en
Priority claimed from PCT/JP2004/006657 external-priority patent/WO2005073220A1/en
Application filed by Астеллас Фарма Инк. (Jp), Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк. (Jp)
Publication of RU2007119067A publication Critical patent/RU2007119067A/en
Application granted granted Critical
Publication of RU2351327C2 publication Critical patent/RU2351327C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Claims (6)

1. Фармацевтическая композиция для лечения синдрома раздраженного кишечника у женщин с преобладанием диареи, содержащая от 0,002 до 0,02 мг гидрохлорида рамозетрона как суточную дозу или эквивалентное молярное количество рамозетрона или другой его фармацевтически приемлемой соли в качестве активного ингредиента.1. A pharmaceutical composition for treating irritable bowel syndrome in women with a predominance of diarrhea, containing from 0.002 to 0.02 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its other pharmaceutically acceptable salt as an active ingredient. 2. Фармацевтическая композиция для снижения выраженности симптома диареи при синдроме раздраженного кишечника у женщин, содержащая от 0,002 до 0,02 мг гидрохлорида рамозетрона как суточную дозу или эквивалентное молярное количество рамозетрона или другой его фармацевтически приемлемой соли в качестве активного ингредиента.2. A pharmaceutical composition for reducing the symptom of diarrhea in irritable bowel syndrome in women, containing from 0.002 to 0.02 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its other pharmaceutically acceptable salt as an active ingredient. 3. Применение гидрохлорида рамозетрона в суточной дозе от 0,002 до 0,02 мг, или рамозетрона, или другой его фармацевтически приемлемой соли в эквимолярном количестве для получения медикамента для лечения синдрома раздраженного кишечника с преобладанием диареи у женщин.3. The use of ramosetron hydrochloride in a daily dose of 0.002 to 0.02 mg, or ramozetron, or its other pharmaceutically acceptable salt in an equimolar amount, to obtain a medicament for the treatment of irritable bowel syndrome with a predominance of diarrhea in women. 4. Применение гидрохлорида рамозетрона в суточной дозе от 0,002 до 0,02 мг, или рамозетрона, или другой его фармацевтически приемлемой соли в эквимолярном количестве для получения медикамента для снижения выраженности диареи у женщин, страдающих синдромом раздраженного кишечника.4. The use of ramosetron hydrochloride in a daily dose of from 0.002 to 0.02 mg, or ramozetron, or its other pharmaceutically acceptable salt in an equimolar amount, to obtain a medication to reduce the severity of diarrhea in women suffering from irritable bowel syndrome. 5. Способ лечения синдрома раздраженного кишечника у женщин с преобладанием симптома диареи, включающий введение пациенту от 0,002 до 0,02 мг гидрохлорида рамозетрона как суточной дозы, или эквивалентного молярного количества рамозетрона, или другой его фармацевтически приемлемой соли.5. A method of treating irritable bowel syndrome in women with a predominant symptom of diarrhea, comprising administering to the patient from 0.002 to 0.02 mg of ramosetron hydrochloride as a daily dose, or an equivalent molar amount of ramosetron, or another pharmaceutically acceptable salt thereof. 6. Способ снижения выраженности симптома диареи при синдроме раздраженного кишечника у женщин, включающий введение пациенту от 0,002 до 0,02 мг гидрохлорида рамозетрона как суточной дозы, или эквивалентного молярного количества рамозетрона, или другой его фармацевтически приемлемой соли.6. A method of reducing the severity of the symptom of diarrhea in irritable bowel syndrome in women, comprising administering to the patient from 0.002 to 0.02 mg of ramosetron hydrochloride as a daily dose, or an equivalent molar amount of ramosetron, or another pharmaceutically acceptable salt thereof.
RU2007119067/15A 2004-01-30 2007-05-22 Medication for treatment of irritate bowels syndrome with diarrhea prevalence RU2351327C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/JP2004/000896 WO2004066998A1 (en) 2003-01-31 2004-01-30 Stable solid medicinal composition for oral administration
JPPCT/JP2004/000896 2004-01-30
JPPCT/JP2004/006657 2004-05-12
PCT/JP2004/006657 WO2005073220A1 (en) 2004-01-30 2004-05-12 Remedy for irritable bowel syndrome with diarrhea

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005127333/15A Division RU2314808C2 (en) 2004-01-30 2005-01-27 Means for treating irritated intestine syndrome cases with diarrhea predominance

Publications (2)

Publication Number Publication Date
RU2007119067A true RU2007119067A (en) 2008-11-27
RU2351327C2 RU2351327C2 (en) 2009-04-10

Family

ID=34650735

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007119067/15A RU2351327C2 (en) 2004-01-30 2007-05-22 Medication for treatment of irritate bowels syndrome with diarrhea prevalence

Country Status (6)

Country Link
EP (1) EP1559446B1 (en)
JP (1) JP3763360B2 (en)
KR (1) KR100746444B1 (en)
CN (1) CN100372533C (en)
ES (1) ES2367896T3 (en)
RU (1) RU2351327C2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4632204B2 (en) * 2005-09-21 2011-02-16 アステラス製薬株式会社 Antidiarrheal irritable bowel syndrome treatment
KR20110045027A (en) * 2008-08-28 2011-05-03 아스텔라스세이야쿠 가부시키가이샤 How to treat irritable bowel syndrome
JP5741433B2 (en) * 2009-06-30 2015-07-01 アステラス製薬株式会社 A therapeutic agent for abnormal defecation in patients with inflammatory bowel disease in remission
JP5938886B2 (en) * 2010-12-14 2016-06-22 アステラス製薬株式会社 Defecation disorder therapeutic agent in active inflammatory bowel disease patients
KR101501889B1 (en) * 2011-10-28 2015-03-12 아스텔라스세이야쿠 가부시키가이샤 Orally disintegrating tablet containing low-dose ramosetron
JP6355806B1 (en) * 2017-09-04 2018-07-11 株式会社三和化学研究所 A therapeutic agent for constipation containing lactulose as an active ingredient
EP4186561A4 (en) 2020-07-21 2023-12-27 Teijin Pharma Limited Light beam irradiation apparatus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6566369B2 (en) * 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients

Also Published As

Publication number Publication date
EP1559446B1 (en) 2011-07-13
CN1764453A (en) 2006-04-26
CN100372533C (en) 2008-03-05
ES2367896T3 (en) 2011-11-10
RU2351327C2 (en) 2009-04-10
KR20060052661A (en) 2006-05-19
JP3763360B2 (en) 2006-04-05
EP1559446A1 (en) 2005-08-03
KR100746444B1 (en) 2007-08-03
JP2005213244A (en) 2005-08-11

Similar Documents

Publication Publication Date Title
UA107578C2 (en) COMBINED DIABETES THERAPY
RU2007119067A (en) MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
EP2444072A3 (en) Non-mucoadhesive film dosage forms
RU2008102911A (en) PHARMACEUTICAL COMPOSITIONS BASED ON GUANFACIN, SUITABLE FOR DAILY ADMINISTRATION AS A UNIT DOSED FORM
RU2008119454A (en) MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS
RU2010107843A (en) BUPROPION HYDROBROMIDE AND ITS THERAPEUTIC APPLICATIONS
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
EA200800075A1 (en) DOSING CIRCUIT FOR WISE
JP2006518731A5 (en)
RU2007132971A (en) METHODS AND MATERIALS WITH TRANS-CLOMIPHENES FOR TREATMENT OF MEN'S INFERTILITY
RU2006128504A (en) SYNTHETIC ANALGETIC PRODUCT AND METHOD OF TREATMENT BASED ON THIS PRODUCT
KR20190087572A (en) Use of carbamate compounds for the prevention, amelioration or treatment of bipolar disorder
RU2004131214A (en) METHODS FOR TREATING COGNITIVE DISORDERS
US20230277523A1 (en) Methods for inhibiting phosphate transport
RU2005135647A (en) COMBINATIONS INCLUDING PAROXETIN AND {1- (R) - (3.5-BIS-TRIFTOR-2-METHYLPHENYL) Ethylmethylamide} -2- (S) - (4-FLUOR-2-METHYLPHENYL) PIPERAZINE-1-CARBETONE DEPRESSIONS AND / OR ALARMS
RU2005127333A (en) MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA
AU2012276476B2 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
CN112437661A (en) Use of benzoic acid or a salt thereof for preventing or treating anti-N-methyl-D-aspartate receptor encephalitis
US11766430B2 (en) Methods of using a phenoxypropylamine compound to treat pain
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
WO2007074170A3 (en) Compositions and methods for the treatment and prevention of disease
RU2007129408A (en) METHOD OF GROWING PIGS IN THE PERIOD OF FEEDING
JP2010518052A (en) Use of antagonists that are compounds of the neurokinin A NK2 receptor for the preparation of drugs useful for the prevention and treatment of sexual dysfunction

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130128